Bristol-Myers to continue M&A activity, R&D chief says

09/23/2009 | Forbes

Bristol-Myers Squibb will pursue more takeovers after its $2.4 billion acquisition of Medarex, said Elliot Sigal, the company's head of research and development. Bristol-Myers expects about a third of its drug portfolio to come from external sources as it prepares to counteract the effects of the so-called patent cliff.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL